| pubmed-article:20600935 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20600935 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:20600935 | lifeskim:mentions | umls-concept:C0073020 | lld:lifeskim |
| pubmed-article:20600935 | lifeskim:mentions | umls-concept:C0015219 | lld:lifeskim |
| pubmed-article:20600935 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:20600935 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:20600935 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20600935 | pubmed:dateCreated | 2011-1-21 | lld:pubmed |
| pubmed-article:20600935 | pubmed:abstractText | Current antiretroviral therapies would greatly benefit from the concurrent removal of integrated HIV-1 proviral DNA from the patient's cells. In this review, we describe an experimental strategy that allowed the engineering and functional analysis of a HIV-1 LTR-specific recombinase (Tre-recombinase). We furthermore provide protocols that are utilized for the investigation of Tre's antiretroviral activity in infected tissue cultures as well as in infected humanized Rag2(-/-)?c(-/-) mice. | lld:pubmed |
| pubmed-article:20600935 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20600935 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20600935 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20600935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20600935 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20600935 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:20600935 | pubmed:issn | 1095-9130 | lld:pubmed |
| pubmed-article:20600935 | pubmed:author | pubmed-author:HauberJoachim... | lld:pubmed |
| pubmed-article:20600935 | pubmed:author | pubmed-author:BuchholzFrank... | lld:pubmed |
| pubmed-article:20600935 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:20600935 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20600935 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:20600935 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20600935 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20600935 | pubmed:pagination | 102-9 | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:meshHeading | pubmed-meshheading:20600935... | lld:pubmed |
| pubmed-article:20600935 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20600935 | pubmed:articleTitle | In vitro evolution and analysis of HIV-1 LTR-specific recombinases. | lld:pubmed |
| pubmed-article:20600935 | pubmed:affiliation | Max-Planck-Institute for Molecular Cell Biology and Genetics, Pfotenhauerstrasse 108, 01307 Dresden, Germany. | lld:pubmed |
| pubmed-article:20600935 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20600935 | pubmed:publicationType | Review | lld:pubmed |
